POLB.L • LSE
Unlock comprehensive alternative data signals to make better investment decisions

Track website visits, page views, unique visitors, and engagement metrics over time to gauge online interest and brand strength.

Monitor Twitter follower growth, engagement rates, and social media presence to understand brand reach and community sentiment.

Analyze TikTok follower trends and viral content performance to measure youth demographic appeal and cultural relevance.

Track Facebook page likes, comments, shares, and post engagement to assess community interaction and brand loyalty.

Monitor Instagram follower growth, engagement rates, and visual content performance across demographics.

Track YouTube channel growth, video views, and subscriber engagement to measure content marketing effectiveness.

Monitor LinkedIn company page followers and professional network growth to assess B2B brand strength and talent attraction.

Track open job positions and hiring trends as a leading indicator of company expansion, contraction, or strategic shifts.

Monitor employee headcount changes on LinkedIn to gauge organizational growth, restructuring, or cost-cutting measures.

Analyze sentiment scores from Reddit discussions to understand retail investor mood and potential price momentum.

Track daily news mentions across major publications to measure media attention, PR effectiveness, and market awareness.

View key financial metrics including Revenue, Net Income, EPS, Free Cash Flow, EBITDA, and Total Assets. Access 2-year quarterly charts for Revenue & Income and Free Cash Flow trends.

Analyze technical indicators including 50-day Simple Moving Average (SMA) with price overlay and Relative Strength Index (RSI) charts.
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
You don't hold POLB.L in your mock portfolio yet.
Poolbeg Pharma PLC is currently loss-making, as indicated by its negative EPS and negative P/E ratio. The lack of positive earnings suggests the company is still in a development or early commercialization phase, with investors relying more on future prospects than current profitability. From a pure fundamentals standpoint, the stock remains speculative and financially high risk.
The stock has shown strong recent momentum, rising 14.5% over the last month and trading well above its 200-day moving average. An RSI of 65.02 indicates bullish momentum that is approaching, but not yet in, overbought territory. Technically, the trend is positive, though short-term pullbacks are possible if momentum cools or sentiment reverses.
Alternative data signals for Poolbeg Pharma PLC are modest and mixed, with limited evidence of accelerating commercial activity or investor buzz. The company has no current job openings, suggesting a stable or constrained hiring posture rather than aggressive expansion. Social media presence is small and relatively flat, implying that broader market awareness and retail interest remain limited at this stage.
Poolbeg Pharma PLC presents a technically strong but fundamentally speculative profile. The recent price strength and position above the 200-day moving average are supportive, yet negative earnings and subdued alternative data keep the overall outlook balanced rather than clearly positive. Overall, the stock appears neutral, with upside tied to future execution and catalysts rather than current financial strength.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
Key moves vs recent baseline (last day / last week)
Plain-English summary of the biggest drivers (informational)
Potential risk factors to review
Based on earnings timing, volatility, liquidity and crowd activity. Informational signals only — not investment advice.
Reassess your thesis if any of these occur: